Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.

Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, Yeku O, Del Carmen MG, Spriggs DR, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2210-2219. doi: 10.1073/pnas.1818357116. Epub 2019 Jan 18.


Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.

Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ.

Nat Biotechnol. 2018 Oct;36(9):847-856. doi: 10.1038/nbt.4195. Epub 2018 Aug 13.


Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.

Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ.

Cell Rep. 2018 May 15;23(7):2130-2141. doi: 10.1016/j.celrep.2018.04.051.


Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.

Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ.

Sci Rep. 2017 Sep 5;7(1):10541. doi: 10.1038/s41598-017-10940-8.


Adoptive T-Cell Therapy for Solid Tumors.

Yeku O, Li X, Brentjens RJ.

Am Soc Clin Oncol Educ Book. 2017;37:193-204. doi: 10.14694/EDBK_180328.


Radium-223 and concomitant therapies: prospects and prudence.

Yeku O, Slovin SF.

Transl Androl Urol. 2016 Dec;5(6):968-970. doi: 10.21037/tau.2016.11.04. No abstract available.


Immune Therapy for Prostate Cancer.

Yeku O, Slovin SF.

Cancer J. 2016 Sep/Oct;22(5):334-341. Review.


Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.

Yeku OO, Brentjens RJ.

Biochem Soc Trans. 2016 Apr 15;44(2):412-8. doi: 10.1042/BST20150291. Review.


Metabolism and pharmacokinetics of radium-223 in prostate cancer.

Yeku O, Slovin SF.

Expert Opin Drug Metab Toxicol. 2015 May;11(5):843-9. doi: 10.1517/17425255.2015.1021332. Epub 2015 Mar 4. Review.


A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.

Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, Lee S, Kirkwood JM.

J Transl Med. 2014 Jan 23;12:19. doi: 10.1186/1479-5876-12-19.


Breast Mass and Lytic Bone Lesions: A Rare Presentation of Non-Hodgkin's Lymphoma Arising in the Breast.

Ali H, Yeku O, Giesler D, Campbell-Massa R, Gao F, Amjad AI.

Case Rep Oncol Med. 2013;2013:547171. doi: 10.1155/2013/547171. Epub 2013 Oct 21.


Phosphatidylinositol-4-phosphate-5-kinase alpha deficiency alters dynamics of glucose-stimulated insulin release to improve glucohomeostasis and decrease obesity in mice.

Huang P, Yeku O, Zong H, Tsang P, Su W, Yu X, Teng S, Osisami M, Kanaho Y, Pessin JE, Frohman MA.

Diabetes. 2011 Feb;60(2):454-63. doi: 10.2337/db10-0614.


The phospholipase D1 pathway modulates macroautophagy.

Dall'Armi C, Hurtado-Lorenzo A, Tian H, Morel E, Nezu A, Chan RB, Yu WH, Robinson KS, Yeku O, Small SA, Duff K, Frohman MA, Wenk MR, Yamamoto A, Di Paolo G.

Nat Commun. 2010;1:142. doi: 10.1038/ncomms1144.


Rapid amplification of cDNA ends (RACE).

Yeku O, Frohman MA.

Methods Mol Biol. 2011;703:107-22. doi: 10.1007/978-1-59745-248-9_8.


Identification of alternative transcripts using rapid amplification of cDNA ends (RACE).

Yeku O, Scotto-Lavino E, Frohman MA.

Methods Mol Biol. 2009;590:279-94. doi: 10.1007/978-1-60327-378-7_18.


5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis.

Su W, Yeku O, Olepu S, Genna A, Park JS, Ren H, Du G, Gelb MH, Morris AJ, Frohman MA.

Mol Pharmacol. 2009 Mar;75(3):437-46. doi: 10.1124/mol.108.053298. Epub 2008 Dec 8.

Supplemental Content

Support Center